SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Qualified Opinion who wrote (4294)4/17/2003 11:27:29 AM
From: Qualified Opinion  Respond to of 10345
 
Excerpt from Biogen article :

"This summer, Biogen and its partner, Elan Corp. (ELN), expect to announce Phase III results for Antegren, natalizumab, in Crohn's disease. Mr. Mullen said the company hopes to file for FDA approval for this indication by the end of this year, or early next. The companies will seek approval for a multiple sclerosis indication shortly after that, Mr. Mullen said."

Link:http://biz.yahoo.com/djus/030417/1103000767_1.html


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News